Welcome to our dedicated page for Acme United SEC filings (Ticker: ACU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acme United Corporation (ACU) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8‑K and, through the SEC’s EDGAR system, other periodic and transactional filings that describe Acme United’s financial condition, operations and material events.
Recent Form 8‑K filings for Acme United report material events such as quarterly financial results and financing arrangements. For example, the company has filed 8‑K reports announcing results of operations and financial condition for quarters ended June 30 and September 30, with press releases attached as exhibits. Another 8‑K describes Amendment No. 11 to the company’s Loan and Security Agreement with HSBC Bank USA, N.A., extending the maturity of a secured revolving credit facility.
Through its SEC filings, Acme United discloses information about its jurisdiction of incorporation, commission file number, and principal office location in Shelton, Connecticut. Filings also identify officers who sign the reports and reference attached exhibits, such as loan amendments and earnings press releases. These documents complement the company’s earnings materials by providing formal regulatory context for reported results and financing activities.
On Stock Titan, investors can use AI‑powered tools to review and interpret Acme United’s SEC filings. Real‑time updates from EDGAR surface new 8‑K, 10‑Q, 10‑K and related forms as they are filed, while AI summaries highlight key points such as changes in credit facilities, reported net sales and income figures, and other material disclosures. Users can also locate information relevant to risk factors discussed in forward‑looking statement sections of press releases that are incorporated by reference into SEC filings.
For research on ACU, this filings page serves as a starting point to examine the company’s official regulatory history, including current reports, periodic reports, and material agreements as disclosed to the SEC.
ACME United Corporation reported the results of its 2026 Annual Meeting of Shareholders held on April 27, 2026. Shareholders elected all seven director nominees, each receiving over 2.82 million votes for, with relatively few votes withheld.
Investors approved an amendment to the 2022 Employee Stock Option Plan with 1,951,474 votes for and 925,794 against, and supported a non-binding advisory resolution on named executive officer compensation with 2,775,611 votes for and 102,051 against. Shareholders also ratified the appointment of CBIZ CPA's, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 3,413,803 votes in favor.
Acme United Corporation reported higher sales but lower profits for the quarter ended March 31, 2026. Net sales rose to $52.3 million from $46.0 million a year earlier, a 14% increase, or 6% growth excluding the My Medic acquisition.
Net income declined to $1.0 million, or $0.24 per diluted share, from $1.7 million, or $0.41 per diluted share, as higher cost of sales and operating expenses offset revenue gains. The company cited tariff-related costs, enhanced quality assurance spending at the Med-Nap facility, and rising employee healthcare costs as key drivers.
Acme highlighted contributions from the recently acquired My Medic business, which has annual sales of $19 million but minimal first-quarter profit due to seasonality. U.S., European, and Canadian segments all posted double-digit sales growth in U.S. dollars. Bank debt less cash increased to $38.6 million, reflecting the My Medic acquisition, a German product line purchase, dividends, a new Tennessee facility, and inventory builds to mitigate supply risks from the conflict in Iran.
Acme United Corporation had a Schedule 13G/A amendment reporting that The Capital Management Corporation beneficially owned 500,967.30 shares of Common stock, representing 13.2% of the class as of 03/31/2026. The filing states sole voting power of 496,192.30 shares and sole dispositive power of 500,967.30 shares. The filing was signed by Pamela Simms as Compliance Officer on 04/02/2026.
Acme United Corporation is asking shareholders to vote at a virtual 2026 annual meeting on April 27, 2026 at 11:00 a.m. Eastern via www.virtualshareholdermeeting.com/ACU2026. Shareholders of record on March 10, 2026, when 3,808,225 common shares were outstanding, may vote online, by phone, mail or during the meeting.
Seven incumbent directors are nominated for one-year terms, including Chairman and CEO Walter C. Johnsen and President and COO Brian S. Olschan. Shareholders are also asked to approve an amendment to the 2022 Employee Stock Option Plan, increasing the shares reserved for options from 500,000 to 700,000, an advisory say-on-pay resolution for named executive officers, and ratification of CBIZ CPAs, P.C. as independent auditor for 2026.
Directors and executive officers as a group beneficially own 1,196,551 shares, or 29.5% of the common stock. In 2025, total compensation was $1,669,401 for CEO Walter C. Johnsen, $1,397,357 for President and COO Brian S. Olschan, and $928,724 for CFO Paul G. Driscoll, including salary, bonuses and stock option awards.
Acme United Corporation reported modest growth for 2025, with net sales of $196.5 million, up 1% from 2024, and net income of $10.2 million. Gross margin held steady at 39.4%, while operating income rose slightly to $14.7 million as first aid and medical products drove performance.
The company continued shifting toward healthcare, with first aid and medical products reaching about 66% of sales and the Elite First Aid and My Medic businesses expanding its trauma and emergency response portfolio. Bank debt was reduced, leaving $53.1 million available under a $65 million credit facility, supporting acquisitions, dividends, and growth investments.
ACME United Corp director Susan H. Murphy reported a bona fide gift of 1,200 shares of common stock on March 3, 2026. The gift transaction was recorded at $44.08 per share. After this disposition, she directly holds 5,967 common shares of ACME United.
ACME United Corp Chief Financial Officer Paul G. Driscoll reported option awards and related transactions in company stock. On March 2, 2026, he received an employee stock option for 15,000 shares at an exercise price of $44.77 per share. According to the vesting schedule, 3,750 option shares will vest on each of March 2, 2027, March 2, 2028, March 2, 2029, and March 2, 2030.
On February 27, 2026, Driscoll exercised 15,000 employee stock options at $21.49 per share and simultaneously disposed of 15,000 shares of common stock to the issuer at $45.88 per share. The option exercise was effected on a net cash settlement basis directly with the company, without the actual issuance of any new shares of underlying common stock. After these transactions, he held 50,398 shares of common stock directly.
ACME UNITED CORP director and President/COO Brian S. Olschann reported option and stock transactions. He received a grant of 20,000 employee stock options at $44.77 per share, with 5,000 options vesting annually from March 2, 2027 through March 2, 2030. He also exercised 15,000 options at $24.92 per share into 15,000 shares of common stock and, in a related transaction with the issuer, disposed of 15,000 common shares at $45.88 per share via a net cash settlement that did not involve issuing new shares.
ACME United Corp director and CEO Walter C. Johnsen reported multiple equity compensation transactions. On March 2, 2026, he received a grant of 25,000 employee stock options at an exercise price of $44.77 per share. According to a footnote, 6,250 options vest on each of March 2, 2027, 2028, 2029, and 2030.
On February 27, 2026, he exercised 30,000 employee stock options at $21.49 per share and acquired 30,000 shares of common stock through this derivative exercise. The same day, he disposed of 30,000 common shares to the issuer at $45.88 per share. A footnote states this option exercise was settled on a net cash basis directly with the issuer and did not involve the actual issuance of any underlying common shares.